The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,971.00
Bid: 1,970.00
Ask: 1,972.00
Change: 11.00 (0.56%)
Spread: 2.00 (0.102%)
Open: 1,994.00
High: 2,000.00
Low: 1,959.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: Hikma, PV Crystalox, retail sales

Wed, 15th Aug 2012 17:57

Acquisitions are set to put a gloss on the interim results of pharmaceuticals firm Hikma on Thursday.Peel Hunt is expecting the group to report sales of more than $500m, up 25% on the first half of last year when, admittedly, results had been negatively affected by the so-called Arab Spring.Sales will be down slightly over the $523m achieved in the second half of last year, the broker predicts, "with the problems in US generics (FDA-enforced shut down) offsetting the additional pro-forma sales from the Moroccan acquisition, which made only a three-month contribution last year"One thing to watch out for is the EBITA [earnings before interest, tax and amortisation] margin, which Peel Hunt thinks will likely take a hit from a competitive pricing environment for generic drugs in the US and continued wage pressure in the Middle East & North Africa (MENA) region. Peel Hunt has pencilled in a margin decline of six-tenths to eight-tenths of a percentage point. "We expect margins (and the tax rate) to benefit further as more Generics manufacturing is transferred to Jordan (up to 50% is still targeted). Hikma's net debt to EBITDA [EBITA + depreciation] stands well within covenants and further bolt-on acquisitions remain possible, with Turkey high up management ambitions. Furthermore, acceleration of product development and a move into higher-value treatments for chronic diseases remain key to organic growth across MENA," Peel Hunt said. Interim results from struggling solar panel maker PV Crystalox could reveal whether the company is going to stick or twist in terms of holding on for an upturn in average selling prices.The group has received a €90m one-off payment in compensation for a contract cancellation, which should ensure it makes a first half profit, probably somewhere in the €70m region.As to what to do with the cash windfall, the group is expected to reveal whether it will essentially run the business for cash from now on.UK retail sales data for July will cover a period between the end of the Queens Jubilee celebration and Euro 2012 and the start of the Olympics, so analysis of underlying trends may be easier than of late - notwithstanding the weather effect, of course.Economists at Credit Suisse think UK Retail Sales, excluding vehicle fuel, will rise 0.3% after advancing 0.2% in June, to a level 2.2% higher than in July 2011.In contrast, Charles Stanley's weekly preview note has July retail sales excluding fuel down 0.2% in July, and up 1.7% year-on-year, so confusion - like the British weather - still reigns.NTERIMS BATM Advanced Communications Ltd., Cineworld Group, Hikma Pharmaceuticals, PV Crystalox Solar, Talvivaara Mining Company, Xaar INTERNATIONAL ECONOMIC ANNOUNCEMENTS Bloomberg Consumer Confidence (US) (14:45) Building Permits (US) (13:30) Consumer Price Index (EU) (10:00) Continuing Claims (US) (13:30) Harmonised Index of Consumer Prices (EU) (10:00) Housing Starts (US) (13:30) Initial Jobless Claims (US) (13:30) Philadelphia Fed Index (US) (15:00) Q2 Talvivaara Mining Company GMS Aegis Group, Energy Technique IMSS Micro Focus International AGMS IGas Energy, Triad Group UK ECONOMIC ANNOUNCEMENTS Internet Retail Sales (09:30) Retail Sales (09:30) FINAL DIVIDEND PAYMENT DATE F&C Global Smaller Companies, Moss Bros Group, MS InternationalJH
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.